4/27
07:36 pm
lgnd
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook [Yahoo! Finance]
Neutral
Report
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook [Yahoo! Finance]
4/27
03:06 pm
lgnd
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
Low
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
4/27
10:08 am
lgnd
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]
Low
Report
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]
4/27
07:00 am
lgnd
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Low
Report
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
4/22
07:00 am
lgnd
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Low
Report
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
4/15
04:27 pm
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.
4/14
11:10 am
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a "buy" rating on the stock.
4/14
07:00 am
lgnd
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Medium
Report
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
4/4
11:17 am
lgnd
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
Low
Report
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]
3/30
08:11 pm
lgnd
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
Medium
Report
CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]
3/30
05:45 am
lgnd
Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes [Yahoo! Finance]
Low
Report
Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes [Yahoo! Finance]
3/27
09:00 pm
lgnd
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know [Yahoo! Finance]
Low
Report
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know [Yahoo! Finance]
3/26
07:00 am
lgnd
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Low
Report
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
3/24
11:19 am
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a "buy" rating on the stock.
3/18
10:07 am
lgnd
Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model [Seeking Alpha]
Low
Report
Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model [Seeking Alpha]
3/11
02:05 pm
lgnd
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]
Low
Report
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]
3/11
08:03 am
lgnd
Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.
Medium
Report
Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.
3/7
07:53 pm
lgnd
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]
Medium
Report
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]
3/4
07:25 am
lgnd
Ligand to Participate in March Investor Conferences [Yahoo! Finance]
Low
Report
Ligand to Participate in March Investor Conferences [Yahoo! Finance]
3/4
07:00 am
lgnd
Ligand to Participate in March Investor Conferences
Low
Report
Ligand to Participate in March Investor Conferences
3/2
12:12 am
lgnd
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? [Yahoo! Finance]
2/27
10:58 am
lgnd
Ligand Pharmaceuticals (LGND) had its price target raised by Oppenheimer Holdings, Inc. from $275.00 to $277.00. They now have an "outperform" rating on the stock.
Low
Report
Ligand Pharmaceuticals (LGND) had its price target raised by Oppenheimer Holdings, Inc. from $275.00 to $277.00. They now have an "outperform" rating on the stock.
2/26
05:33 pm
lgnd
Ligand Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ligand Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
04:50 pm
lgnd
Ligand Pharma (LGND) Earnings Call Transcript [Yahoo! Finance]
Low
Report
Ligand Pharma (LGND) Earnings Call Transcript [Yahoo! Finance]
2/26
07:59 am
lgnd
Ligand: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ligand: Q4 Earnings Snapshot [Yahoo! Finance]